Global Automated And Rapid Microbiological Tests Market

  • May 2014
  • -
  • Global Industry Analysts
  • -
  • 371 pages

This report analyzes the worldwide markets for Automated And Rapid Microbiological Tests in US$ Thousands by the following End-Use Segments: Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, & Other Automated & Rapid Microbiological Tests), and Non-Clinical Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 103 companies including many key and niche players such as -

Abbott Laboratories
Alere Inc.
Becton Dickinson and Company
bioMerieux SA
Bio-Rad Laboratories, Inc.

Table Of Contents




I. INTRODUCTION, METHODOLOGY and PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation and Reporting Level I-2
Quantitative Techniques and Analytics I-3
Product Definitions and Scope of Study I-3
Clinical Applications I-4
Automated Identification and Susceptibility Systems I-4
Automated Blood Culture Systems I-4
Automated Tuberculosis Systems I-4
Streptococcal Infection Rapid Tests I-4
GC/Chlamydia Rapid Tests I-5
Other Automated and Rapid Microbiological Tests I-5
Non-Clinical Applications I-5


II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1
Global Invitro-Diagnostics Market II-1
Table 1: Global In Vitro Diagnostics (IVD) Market by
Geographic Region (2013): Percentage Share Breakdown of
Revenues for the United States, Europe, and Rest of World
(includes corresponding Graph/Chart) II-1

Table 2: Global In-Vitro Diagnostics Market by Sector (2013):
Percentage Breakdown of Revenues for Hospital and Commercial
Laboratories, Decentralized and Patient Self-Testing, (includes
corresponding Graph/Chart) II-2

Table 3: Global In-Vitro Diagnostics Market by Segment
(2013): Percentage Breakdown of Value Sales for Hematology,
Hemostasis, Immunochemistry, Microbiology, Molecular
Diagnostics, Point-of-Care Diagnostics, Self-Monitoring Blood
Glucose, and Tissue Diagnostics (includes corresponding
Graph/Chart) II-2

Table 4: Global In Vitro Diagnostics Market by Leading Player
(2013): Percentage Share Breakdown of Revenues for Abbott,
Biomerieux, Danaher, JandJ, Roche, Siemens and Others (includes
corresponding Graph/Chart) II-3
Automated and Rapid Microbiological Tests Revolutionize
Microbiological Testing II-3
Evolutionary Battle against Microbes Drives Market Future II-4
Automated Microbiological Tests: A Pesky Gray Area in the
Clinical Diagnostics Market II-5
Instant Detection of Pathogens - A New Epoch in the Fight for
Survival II-5
Traditional Rapid Microbiological Tests Make Way for New,
Probe Tests II-6
Emerging Markets Provide Tremendous Growth Opportunities II-7
Clinical Applications II-8
Table 5: Global Automated and Rapid Microbiological Tests
Market in Clinical Applications by Region: (2014) (includes
corresponding Graph/Chart) II-8

Table 6: Global Automated and Rapid Microbiological Tests
Market in Clinical Applications by Segment: (2014) (includes
corresponding Graph/Chart) II-9
Non-Clinical Applications II-9
Table 7: Global Automated and Rapid Microbiological Tests
Market in Non-Clinical Applications by Region: (2014)
(includes corresponding Graph/Chart) II-10
A Holistic Peek into a Few Noteworthy Trends II-11
The Evolution of Biotechnology - A Crucial Step Ahead in the
Growing Popularity of Rapid Microbial Tests II-11
Point-of-Care Rapid Microbiological Testing: Yet to Realize
Its Full Potential II-12

2. COMPETITION II-14
Table 8: Global Microorganism Identification and Resistance
Tests Market by Leading Player (2013): Percentage Market Share
Breakdown of Value Sales for Becton Dickinson and Co,
BioMerieux, and Others (includes corresponding Graph/Chart) II-14

Table 9: Global Blood Screening Market by Leading Player
(2013): Percentage Market Share Breakdown of Value Sales for
Hologic Gen-Probe, Roche and Others (includes corresponding
Graph/Chart) II-14

Table 10: Global GC-CT Testing Market by Leading Player
(2013): Percentage Market Share Breakdown of Value Sales for
Becton Dickinson and Co, Hologic Gen- Probe, Qiagen NV, Roche
and Others (includes corresponding Graph/Chart) II-15
Competitive Dynamics in the C. Difficile Testing Market II-15
Table 11: Global Molecular Diagnostics Market for Clostridium
difficile by Leading Player (2013): Percentage Breakdown of
Revenues for Becton Dickinson, Cepheid, Meridian and Others
(includes corresponding Graph/Chart) II-15

Table 12: Global Immunoassays Market for Clostridium
difficile by Leading Player (2013): Percentage Breakdown of
Revenues for Meridian and Others (includes corresponding
Graph/Chart) II-16
A List of Select Molecular C. difficile Test Products II-16

3. MARKET DRIVERS AND TRENDS II-17
Increasing Incidence of Infectious Diseases - An Opportunity
Indicator II-17
Table 13: Reported Cases of Major Infections by Select
Geographic Region: 2011 II-17
Rising Healthcare Needs of Aging Global Population - A Growth
Driver II-18
Table 14: Global Population Statistics for the 65+ Age Group
(2012) (includes corresponding Graph/Chart) II-19

Table 15: Elderly Population (65+ Years) as a % of Total
Population (2025) (includes corresponding Graph/Chart) II-20
Rising HIV Prevalance - A Key Opportunity Indicator II-20
Some Significant HIV Statistics by Region: 2011 II-21
Table 16: Global Prevalence of HIV Infection in 2012 by
Region (in Millions) (includes corresponding Graph/Chart) II-22

Table 17: Newly Infected HIV Population in 2012 by Region
(in Millions) (includes corresponding Graph/Chart) II-23

Table 18: Global HIV Related Deaths in 2012 by Region (in
Millions) (includes corresponding Graph/Chart) II-24

Table 19: Top Twelve Countries in Apac with The Highest Hiv
Incidence (2012) (includes corresponding Graph/Chart) II-25

Table 20: Global HIV Prevalence among Adults and Youth in
2010 (includes corresponding Graph/Chart) II-26
Rapid HIV Tests: A New Age Diagnostic Weapon against the
Killer Disease II-26
Ultra-Rapid HIV-Screening Tests put up a Strong Fight against
HIV-Epidemic II-27
Accuracy/Reliability of Home HIV Testing: A Bone of Contention II-27
Increase in Healthcare Spending in Emerging Markets to Propel
Demand II-28
Table 21: Healthcare Spending as % of GDP in Select Countries
(2011) (includes corresponding Graph/Chart) II-28
Rising Emphasis on Lab Automation to Augur Well for Market Growth II-29
Greater Patient Awareness to Drive Growth II-29
Advancements in Molecular Diagnostics - A Boon II-29
Antibiotic Resistant Bacteria Throws the Spotlight on
Microbial Testing II-30
Influenza - Boosting Rapid Test Prospects II-30
Select FDA-approved Rapid Detection Tests for Flu AandB: (2012) II-31
Automated Blood Culture Systems: The Gold Standard in the
Fight against Bacteremia II-32
Impact of Food Scares on Rapid Microbiological Tests Market II-33
Stringent Norms Necessitate Microbial Food Safety Testing II-34
Rapid Screening Gains Preference over Traditional Food Testing
Procedures II-34
Leading Food Processors Resort to Rapid Microbiological Testing II-35
Food Packages of the Future Ingrained with Microbial Alert
Systems II-36
Poultry Industry Embraces Rapid Microbiological Testing
Technologies II-36
Rapid Microbiological Tests Gain Significance in the Pharma
Industry II-36
Key Advantages of Rapid Microbiological Tests for Pharma- In
a Nutshell II-37
Growth Directâ„¢ System Creates Waves in the Pharmaceutical
Quality Control II-38

4. KEY ISSUES CONFRONTING THE RAPID MICROBIOLOGICAL TESTS MARKET II-39
Validation: An Imperative Prerequisite II-39
Obtaining Regulatory Approval: A Major Non-Technical Hindrance II-39
Non-Conformance to Testing Requirements: A Weighty Concern II-39
Technical and Cost Issues Impede the Uptake of Rapid
Microbiological Tests in the Food Sector II-40

5. PRODUCT/TECHNOLOGY OVERVIEW II-41
Automated and Rapid Microbiological Tests: A Definition II-41
How Does a Rapid Test Work? II-41
Enabling Technologies of Automated and Rapid Microbiological Tests II-42
Growth-based Technologies II-42
Viability-based Technologies II-42
Cellular-Component or Artifact-based Technologies II-42
Genomics/Proteomics II-42
Microarrays/Microfluidics II-42
DNA Microchips/Probes II-43
Polymerase Chain Reaction (PCR) II-43
Immunoassay II-44
Nucleic Acid Testing (NAT) II-44
Nucleic Acid Probes II-45
Signal-Amplified Tests II-45
Nucleic Acid Amplification Tests II-45
Traditional Methods with Computer-Aided Imaging II-46
Combination Methods II-46

6. APPLICATION AREAS OF AUTOMATED AND RAPID MICROBIOLOGICAL
TESTS- A REVIEW II-47
Clinical Applications II-47
Automated Identification and Susceptibility Systems II-47
Automated Blood Culture Systems II-47
Automated Tuberculosis Systems II-47
Streptococcus Infection Rapid Tests II-47
Streptococcus A Rapid Tests II-48
Streptococcus B Rapid Tests II-48
GC/Chlamydia Rapid Tests II-49
Other Automated and Rapid Microbiological Tests II-49
Respiratory Rapid Tests II-49
RSV/ Influenza Rapid Tests II-50
Gastrointestinal Rapid Tests II-50
Giardia Lamblia Rapid Tests II-50
H. Pylori Rapid Tests II-50
Cryptosporidium Rapid Tests II-51
C. Difficile Rapid Tests II-51
STD Rapid Tests II-52
HIV Rapid Tests II-52
Advantages of Rapid HIV Testing II-53
Disadvantages of Rapid HIV Testing II-53
Syphilis Rapid Tests II-53
Applications in Non-Clinical Investigations II-54
Food/Water Safety Tests II-54
Food Safety Testing: A Lucrative Application Area II-54
qPCR Application in Food Microbiology: Study of Select
Micro-Organisms by Target Gene and Food Substrate II-55
Rapid Microbiological Methods in Pharmaceutical Sector II-56
Limitations II-57
Advantages II-57
Applications in Pharmaceutical Sector II-57
Environmental Tests II-58
Other Miscellaneous Applications II-58

7. PRODUCT INNOVATIONS/INTRODUCTIONS II-59
Neogen Rolls Out NeoFilmTM for Microbial Tests II-59
bioMerieux Unveils TEMPO® AC Automated Test II-59
Neogen Introduces New Soleris® Rapid Assays for Sterility Testing II-59
Pall Introduces GeneDisc II-60
Rapid Micro Biosystems to Launch Next-Generation Growth
DirectTM Systems II-60
Bruker Unveils Single-Use MALDI BiotargetTM Sample Plates II-60
Becton, Dickinson and Company Introduces BD BACTECâ„¢ SafePod II-61
Applied Visual Sciences Introduces TBDxVâ„¢ TB Diagnostic Aid II-61
Neogen Introduces Faster Soleris® Test for Detecting Mold and
Yeast II-61
BioControl Systems Develops PCR for Detecting Non-O157
Serotypes of STEC II-62
InDevR Introduces New Virus Counter II-62
MicroPhage Receives Approval from FDA for KeyPathâ„¢ MRSA/MSSA
Blood Culture Test - BT II-62
Health Canada Approves DuPont’s BAX® System Real-Time Assay II-63
Neogen Receives Approval from AOAC for Reveal 2.0 Test II-63
Life Technologies and University of Pennsylvania School of
Veterinary Medicine Introduce TaqMan® Salmonella enteritidis
Detection Kit II-63
AdvanDX Obtains 510(k) Clearance from US FDA for GNR Traffic
Light™ PNA FISH® II-63
Abbott Laboratories Introduces PLEX-IDâ„¢ Biothreat Assay II-63
bioMerieux Receives FDA Clearance for NucliSENS EasyQ MRSA II-64
BD Launches BD Maxâ„¢ Open System II-64
Luxcel Biosciences and Mocon Develop GreenLightâ„¢900 Series II-64
Bruker Launches pTDâ„¢ for Homeland Security II-64
Hygiena International Launches EnSURE II-65

8. RECENT INDUSTRY ACTIVITY II-66
MedMira Secures Approval from COFEPRIS II-66
MedMira Secures Marketing Approval for Enriched Version of
Reveal® Rapid HIV Test (Europe) II-66
Corgenix Medical Announces Expansion of Viral Hemorrhagic
Fever Rapid Testing Facilities in Sierra Leone II-66
MedMira and National Research Council of Canada Ink
Collaborative Research Agreement II-67
CML HealthCare Installs BD Kiestra Total Laboratory Automation
System at Central Laboratory II-67
BioMerieux Obtains FDA Clearance for Vitek MS Clinical
Microbiology System II-67
Cepheid Obtains FDA Clearance for Xpert® MTB/RIF Test II-68
Rapid Micro Biosystems Receives Funding from Various Capital
Ventures to Support Growth DirectTM System II-68
Instant BioScan Rolls Out Real-Time Microbial System for Water II-68
Becton, Dickinson and Company Takes Over KIESTRA Lab Automation II-69
Duzen and Bruker Enter into Exclusive Framework Agreement II-69
Bruker Enters into Collaboration with Special Bacteriology
Reference Laboratory II-69
Terumo Completes Merger with CaridianBCT II-70
LabCorp to Develop a Novel Laboratory-based Antibiotic
Susceptibility Assay II-70
Nanosphere Receives FDA Authorization for Marketing BC-GP Test II-70
BD Diagnostics Introduces New Molecular Test II-71
BD Diagnostics Receives Approval for Plastic Blood Culture
Bottles II-71
Cepheid Develops Xpert CT/NG and Xpert CT Next-Generation
Molecular Products II-71
BIT Analytical Instruments and DRG Diagnostics Launch New
Product for Analyzing Immunoassays Parameters II-72
Verigene System Introduces Instrument for Automatic Bacterial
Identification in Blood Culture Test II-72
Block Scientific Supplies BACTECTM 9000 Range of Blood Culture
Systems II-72
Valio Signs Agreement with DSM II-73
CML HealthCare Inks Agreement with Becton, Dickinson and Company II-73
Abbott Secures CE Marking for PLEX-IDTM System and Clinical
Assays II-73
Abbott Laboratories and Genetics Laboratory to Enter into
Collaboration for Development of Molecular Diagnostic Test II-74
Bruker Extends Distribution Agreement with Francisco Soria
Melguizo II-74
Laboratory Viollier and Bruker Extend Existing Agreement II-74
Thermo Fisher Scientific Receives FDA Approval for Sensititre
OptiRead Automated Fluorometric Plate Reading System II-75
Magellan Biosciences Obtains FDA Approval for Sensititre AIM
Automated Inoculation Delivery System II-75
bioMerieux Receives FDA Approval for NucliSENS EasyQ® MRSA II-75
BD Diagnostics Obtains FDA Approval for BD ProbeTecTM Assays II-76
Signature Mapping Medical Sciences Receives Order from Aurum
Institute for Health Research II-76
Mindray Medical Takes Over Stake in Hunan Changsha Tiandiren
Biotech II-76
UL Acquires MDT and MDRS II-76
Thermo Fisher Scientific Takes over TREK Diagnostic Systems II-77
Eurofins Acquires Lancaster Laboratories II-77
Polyplus-Transfection Inks Agreement with ExcellGene for
Transfection Reagents II-77
Merck Acquires Microbiology Division of Biotest II-77
UL Establishes New Water Testing Laboratory in India II-78
Neogen Obtains FDA Clearance Reveal for Salmonella Enteritidis
(SE) Fast Test II-78
Sekisui Chemical Acquires Diagnostic Products Business of Genzyme II-78
Dynacare Laboratories Acquires Bruker MALDI Biotyper System II-79
Magellan Biosciences Enters into Partnership with miacom
Diagnostics II-79
Lonza Signs Distribution Agreement with Roche II-79
BD Enters into Collaboration with Bruker Daltonics II-79
Seegene Enters into Partnership with Molzym II-79
bioMerieux Enters into Partnership with Shanghai Institutes
for Biological Sciences II-80
Becton, Dickinson and Company Acquires Global Rights to Market
Micro PRO II-80
Rapid Micro Biosystems Enters Into Partnership with Life
Technologies II-80

9. FOCUS ON SELECT GLOBAL PLAYERS II-81
Abbott Laboratories (USA) II-81
Abbott Diagnostics (US) II-81
Alere Inc. (US) II-82
Becton Dickinson and Company (US) II-82
bioMerieux SA (France) II-83
bioMerieux, Inc. (USA) II-83
Bio-Rad Laboratories, Inc (US) II-84
Cellabs Pty Ltd (Australia) II-84
Celsis International Plc. (UK) II-84
Coris BioConcept (Belgium) II-85
F. Hoffmann-La Roche Ltd. (Switzerland) II-85
Hologic Gen-Probe Incorporated (US) II-86
MedMira, Inc. (Canada) II-87
Meridian Biosciences, Inc. (US) II-87
Orasure Technologies, Inc. (US) II-87
Orion Diagnostica Oy (Finland) II-88
Quidel Corp. (US) II-88
Sekisui Diagnostics (Japan) II-89
Siemens Healthcare Diagnostics, Inc. (USA) II-89
Thermo Fisher Scientific, Inc. (US) II-90
Oxoid Limited (UK) II-90

10. GLOBAL MARKET PERSPECTIVE II-92
Table 22: World Recent Past, Current and Future Analysis for
Automated and Rapid Microbiological Tests by Geographic Region-
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Latin America and Rest of World Independently Analyzed with
Annual Sales Figures in US$ Thousand for Years 2013 through
2020 (includes corresponding Graph/Chart) II-92

Table 23: World Historic Review for Automated and Rapid
Microbiological Tests by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan), Latin America
and Rest of World Independently Analyzed with Annual Sales
Figures in US$ Thousand for Years 2006 through 2012 (includes
corresponding Graph/Chart) II-93

Table 24: World 15-Year Perspective for Automated and Rapid
Microbiological Tests by Geographic Region - Percentage
Breakdown of Dollar Sales for US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World for Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) II-94

Table 25: World Recent Past, Current and Future Analysis for
Automated and Rapid Microbiological Tests in Clinical
Applications by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World Independently Analyzed with Annual Sales Figures in US$
Thousand for Years 2013 through 2020 (includes corresponding
Graph/Chart) II-95

Table 26: World Historic Review for Automated and Rapid
Microbiological Tests in Clinical Applications by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Latin America and Rest of World Independently Analyzed
with Annual Sales Figures in US$ Thousand for Years 2006
through 2012 (includes corresponding Graph/Chart) II-96

Table 27: World 15-Year Perspective for Automated and Rapid
Microbiological Tests in Clinical Applications by Geographic
Region - Percentage Breakdown of Dollar Sales for US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan), Latin America
and Rest of World for Years 2006, 2014 and 2020 (includes
corresponding Graph/Chart) II-97

Table 28: World Recent Past, Current and Future Analysis for
Automated and Rapid Microbiological Tests in Clinical
Applications by Segment - Automated Identification and
Susceptibility Systems, Automated Blood Culture Systems,
Automated Tuberculosis Systems, Streptococcal Infection Rapid
Tests, GC/Chlamydia Rapid Tests, and Other Automated and Rapid
Microbiological Tests Independently Analyzed with Annual Sales
Figures in US$ Thousand for Years 2013 through 2020 (includes
corresponding Graph/Chart) II-98

Table 29: World Historic Review for Automated and Rapid
Microbiological Tests in Clinical Applications by Segment -
Automated Identification and Susceptibility Systems, Automated
Blood Culture Systems, Automated Tuberculosis Systems,
Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests,
and Other Automated and Rapid Microbiological Tests
Independently Analyzed with Annual Sales Figures in US$
Thousand for Years 2006 through 2012 (includes corresponding
Graph/Chart) II-99

Table 30: World 15-Year Perspective for Automated and Rapid
Microbiological Tests in Clinical Applications by Segment -
Percentage Breakdown of Dollar Sales for Automated
Identification and Susceptibility Systems, Automated Blood
Culture Systems, Automated Tuberculosis Systems, Streptococcal
Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other
Automated and Rapid Microbiological Tests for Years 2006, 2014 and
2020 (includes corresponding Graph/Chart) II-100

Table 31: World Recent Past, Current and Future Analysis for
Automated Identification and Susceptibility Systems in Clinical
Applications by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World Independently Analyzed with Annual Sales Figures in US$
Thousand for Years 2013 through 2020 (includes corresponding
Graph/Chart) II-101

Table 32: World Historic Review for Automated Identification and
Susceptibility Systems in Clinical Applications by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Latin America and Rest of World Independently Analyzed
with Annual Sales Figures in US$ Thousand for Years 2006
through 2012 (includes corresponding Graph/Chart) II-102

Table 33: World 15-Year Perspective for Automated
Identification and Susceptibility Systems in Clinical
Applications by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World for Years
2006, 2014 and 2020 (includes corresponding Graph/Chart) II-103

Table 34: World Recent Past, Current and Future Analysis for
Automated Blood Culture Systems in Clinical Applications by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World
Independently Analyzed with Annual Sales Figures in US$
Thousand for Years 2013 through 2020 (includes corresponding
Graph/Chart) II-104

Table 35: World Historic Review for Automated Blood Culture
Systems in Clinical Applications by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin
America and Rest of World Independently Analyzed with Annual
Sales Figures in US$ Thousand for Years 2006 through 2012
(includes corresponding Graph/Chart) II-105

Table 36: World 15-Year Perspective for Automated Blood
Culture Systems in Clinical Applications by Geographic Region
- Percentage Breakdown of Dollar Sales for US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and Rest
of World for Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) II-106

Table 37: World Recent Past, Current and Future Analysis for
Automated Tuberculosis Systems in Clinical Applications by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World
Independently Analyzed with Annual Sales Figures in US$
Thousand for Years 2013 through 2020 (includes corresponding
Graph/Chart) II-107

Table 38: World Historic Review for Automated Tuberculosis
Systems in Clinical Applications by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin
America and Rest of World Independently Analyzed with Annual
Sales Figures in US$ Thousand for Years 2006 through 2012
(includes corresponding Graph/Chart) II-108

Table 39: World 15-Year Perspective for Automated Tuberculosis
Systems in Clinical Applications by Geographic Region -
Percentage Breakdown of Dollar Sales for US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and Rest
of World for Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) II-109

Table 40: World Recent Past, Current and Future Analysis for
Streptococcal Infection Rapid Tests in Clinical Applications
by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World
Independently Analyzed with Annual Sales Figures in US$
Thousand for Years 2013 through 2020 (includes corresponding
Graph/Chart) II-110

Table 41: World Historic Review for Streptococcal Infection
Rapid Tests in Clinical Applications by Geographic Region -
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Latin America and Rest of World Independently Analyzed with
Annual Sales Figures in US$ Thousand for Years 2006 through
2012 (includes corresponding Graph/Chart) II-111

Table 42: World 15-Year Perspective for Streptococcal
Infection Rapid Testsin Clinical Applications by Geographic
Region - Percentage Breakdown of Dollar Sales for US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan), Latin America
and Rest of World for Years 2006, 2014 and 2020 (includes
corresponding Graph/Chart) II-112

Table 43: World Recent Past, Current and Future Analysis for
GC/Chlamydia Rapid Tests in Clinical Applications by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World
Independently Analyzed with Annual Sales Figures in US$
Thousand for Years 2013 through 2020 (includes corresponding
Graph/Chart) II-113

Table 44: World Historic Review for GC/Chlamydia Rapid Tests
in Clinical Applications by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan), Latin America
and Rest of World Independently Analyzed with Annual Sales
Figures in US$ Thousand for Years 2006 through 2012 (includes
corresponding Graph/Chart) II-114

Table 45: World 15-Year Perspective for GC/ Chlamydia Rapid
Tests in Clinical Applications by Geographic Region -
Percentage Breakdown of Dollar Sales for US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and Rest
of World for Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) II-115

Table 46: World Recent Past, Current and Future Analysis for
Other Automated and Rapid Microbiological Tests in Clinical
Applications by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World Independently Analyzed with Annual Sales Figures in US$
Thousand for Years 2013 through 2020 (includes corresponding
Graph/Chart) II-116

Table 47: World Historic Review for Other Automated and Rapid
Microbiological Tests in Clinical Applications by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Latin America and Rest of World Independently Analyzed
with Annual Sales Figures in US$ Thousand for Years 2006
through 2012 (includes corresponding Graph/Chart) II-117

Table 48: World 15-Year Perspective for Other Automated and
Rapid Microbiological Tests in Clinical Applications by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Latin America and Rest of World for Years 2006, 2014 and 2020
(includes corresponding Graph/Chart) II-118

Table 49: World Recent Past, Current and Future Analysis for
Automated and Rapid Microbiological Tests in Non-Clinical
Applications by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World Independently Analyzed with Annual Sales Figures in US$
Thousand for Years 2013 through 2020 (includes corresponding
Graph/Chart) II-119

Table 50: World Historic Review for Automated and Rapid
Microbiological Tests in Non-Clinical Applications by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World
Independently Analyzed with Annual Sales Figures in US$
Thousand for Years 2006 through 2012 (includes corresponding
Graph/Chart) II-120

Table 51: World 15-Year Perspective for Automated and Rapid
Microbiological Tests in Non-Clinical Applications by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Latin America and Rest of World for Years 2006, 2014 and 2020
(includes corresponding Graph/Chart) II-121


III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Current and Future Analysis III-1
Changing Healthcare Industry Dynamics Affect Rapid and
Automated Microbiological Tests Market III-1
Table 52: Healthcare Spending as a % of GDP (includes
corresponding Graph/Chart) III-1
Positive Outlook for Rapid and Automated Microbiological
Tests Market III-2
Rapidly Ageing Demographics Drive Growth III-4
Table 53: North American Aging Population by Age Group:
1975-2050 (includes corresponding Graph/Chart) III-4
Competition III-5
Tracking Trends Across Product Segments III-5
Automated Identification and Susceptibility Systems III-5
Growing Popularity of FDA-Approved Automated
Susceptibility Testing Equipment III-5
STD Rapid Tests III-6
Market Shares of Leading Players III-6
Table 54: The US Market for Syphilis Rapid Tests by
Leading Player (2013) - Percentage Breakdown of Value
Sales for Alere, Becton Dickinson and Others (includes
corresponding Graph/Chart) III-6
HIV Rapid Testing Market III-7
Gastrointestinal Rapid Tests III-7
Table 55: The US Market for Rotavirus Rapid Tests by
Leading Player (2013) - Percentage Breakdown of Value
Sales for Meridian Biosciences, Thermo Fisher Scientific,
and Others (includes corresponding Graph/Chart) III-7

Table 56: The US Market for Giardia Rapid Tests by Leading
Player (2013) - Percentage Breakdown of Value Sales for
Becton Dickinson, Meridian Biosciences, and Oxoid
(includes corresponding Graph/Chart) III-7
Respiratory Rapid Tests III-8
Competition III-8
Market Share Data of Leading Players III-8
Table 57: The US Trichomonas Testing Market by Leading
Player (2013): Percentage Breakdown of Revenues for
Becton Dickinson and Co, and Hologic GenProbe Inc
(includes corresponding Graph/Chart) III-8

Table 58: The US Market for Influenza Rapid Tests by
Leading Player (2013) - Percentage Breakdown of Value
Sales for Becton Dickinson, Quidel, Thermo Fisher
Scientific and Others (includes corresponding
Graph/Chart) III-8

Table 59: The US Market for RSV Rapid Tests by Leading
Player (2013) - Percentage Breakdown of Value Sales for
Becton Dickinson, Binax, Thermo Fisher Scientific and
Others (includes corresponding Graph/Chart) III-9

Table 60: The US Market for Tuberculosis Rapid Tests by
Leading Player (2013) - Percentage Breakdown of Value
Sales for Becton Dickinson and Hologic Gen-Probe
(includes corresponding Graph/Chart) III-9

Table 61: The US Market for M. Pneumoniae Rapid Tests by
Leading Player (2013) - Percentage Breakdown of Value
Sales for Meridian Biosciences and Oxoid (includes
corresponding Graph/Chart) III-9

Table 62: The US Market for Mononucleosis Rapid Tests by
Leading Player (2013) - Percentage Breakdown of Value
Sales for Alere, Oxoid, Quidel and Others (includes
corresponding Graph/Chart) III-10
Streptococcus Infection Rapid Tests III-10
Table 63: The US Market for Streptococcus A Rapid Tests by
Leading Player (2013) - Percentage Breakdown of Value
Sales for Becton Dickinson, Quidel, Thermo Fisher
Scientific, and Others (includes corresponding
Graph/Chart) III-10
Testing Practices of the US Food Industry III-11
Table 64: US Food Safety Testing Market by Contaminant
(2013): Percentage Breakdown of Value Sales for Pathogens,
GMOs, Toxins, Residues and Others (includes corresponding
Graph/Chart) III-12
Increasing Demand for Microbiology Tests in the Food Sector III-12
Table 65: US Microbiological Food Safety Tests by Type
(2013): Percentage Share Breakdown in terms of Number of
Tests for Routine Tests and Pathogen Tests (includes
corresponding Graph/Chart) III-12
Tackling the Burden of Food Borne Illnesses III-13
Table 66: Food-borne Illnesses, Hospitalizations and Deaths
in the US (2012): Percentage Share Breakdown for Known
Pathogens and Unspecified Agents (includes corresponding
Graph/Chart) III-13

Table 67: Leading Pathogens Causing Food- borne Illnesses
in the US (2012): Percentage Share Breakdown of Number of
Illnesses by Known Pathogens - Norovirus, Salmonella
nontyphoidal, Clostridium perfringens, Campylobacter spp.,
Staphylococcus aureus, and Others (includes corresponding
Graph/Chart) III-14

Table 68: Leading Food-borne Pathogens Causing
Hospitalizations in the US (2012): Percentage Share
Breakdown of Number of Hospitalizations by Known Pathogens-
Salmonella nontyphoidal, Norovirus, Campylobacter spp.,
Toxoplasma gondii, E. coli (STEC) O157, and Others
(includes corresponding Graph/Chart) III-14

Table 69: Leading Food-borne Pathogens Causing Deaths in
the US (2012): Percentage Share Breakdown of Number of
Deaths by Known Pathogens - Salmonella nontyphoidal,
Norovirus, Campylobacter spp., Toxoplasma gondii, E. coli
(STEC) O157, and Others (includes corresponding
Graph/Chart) III-14
Product Launches III-15
Strategic Corporate Developments III-16
Select Key Players III-21
B.Market Analytics III-28
Table 70: The US Recent Past, Current and Future Analysis for
Automated and Rapid Microbiological Tests by End-Use
Application - Clinical Applications (Automated
Identification and Susceptibility Systems, Automated Blood
Culture Systems, Automated Tuberculosis Systems,
Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid
Tests, and Other Automated and Rapid Microbiological Tests)
and Non-Clinical Applications Independently Analyzed with
Annual Sales Figures in US$ Thousand for Years 2013 through
2020 (includes corresponding Graph/Chart) III-28

Table 71: The US Historic Review for Automated and Rapid
Microbiological Tests by End-Use Application - Clinical
Applications (Automated Identificationand Susceptibility
Systems, Automated Blood Culture Systems, Automated
Tuberculosis Systems, Streptococcal Infection Rapid Tests,
GC/Chlamydia Rapid Tests, and Other Automated and Rapid
Microbiological Tests) and Non-Clinical Applications
Independently Analyzed with Annual Sales Figures in US$
Thousand for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-29

Table 72: The US 15-Year Perspective for Automated and Rapid
Microbiological Tests by End-Use Application - Percentage
Breakdown of Dollar Sales for Clinical Applications
(Automated Identification and Susceptibility Systems,
Automated Blood Culture Systems, Automated Tuberculosis
Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia
Rapid Tests, and Other Automated and Rapid Microbiological
Tests) and Non-Clinical Applications for Years 2006, 2014 and
2020 (includes corresponding Graph/Chart) III-30

2. CANADA III-31
A.Market Analysis III-31
Current and Future Analysis III-31
Food Safety Testing in Canada III-31
Table 73: Canadian Food-Borne Illnesses by Category (2012):
Percentage Share Breakdown of Number of Illness Caused
through Known Pathogens and Unknown Pathogens (includes
corresponding Graph/Chart) III-32

Table 74: Canadian Food-Borne Illnesses by Pathogen (2012):
Percentage Breakdown of number of Illness Caused by
Norovirus, Clostridium perfringers, Campylobacter spp,
Salmonella spp., non-typhoidal and Others (includes
corresponding Graph/Chart) III-32
Strategic Corporate Developments III-33
MedMira, Inc. - A Key Player III-35
B.Market Analytics III-36
Table 75: Canadian Recent Past, Current and Future Analysis
for Automated and Rapid Microbiological Tests by End-Use
Segment - Clinical Applications (Automated Identification and
Susceptibility Systems, Automated Blood Culture Systems,
Automated Tuberculosis Systems, Streptococcal Infection
Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated and
Rapid Microbiological Tests) and Non-Clinical Applications
Independently Analyzed with Annual Sales Figures in US$
Thousand for Years 2013 through 2020 (includes corresponding
Graph/Chart) III-36

Table 76: Canadian Historic Review for Automated and Rapid
Microbiological Tests by End-Use Segment - Clinical
Applications (Automated Identificationand Susceptibility
Systems, Automated Blood Culture Systems, Automated
Tuberculosis Systems, Streptococcal Infection Rapid Tests,
GC/Chlamydia Rapid Tests, and Other Automated and Rapid
Microbiological Tests) and Non-Clinical Applications
Independently Analyzed with Annual Sales Figures in US$
Thousand for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-37

Table 77: Canadian 15-Year Perspective for Automated and Rapid
Microbiological Tests by End-Use Segment - Percentage
Breakdown of Dollar Sales for Clinical Applications
(Automated Identification and Susceptibility Systems,
Automated Blood Culture Systems, Automated Tuberculosis
Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia
Rapid Tests, and Other Automated and Rapid Microbiological
Tests) and Non-Clinical Applications for Years 2006, 2014 and
2020 (includes corresponding Graph/Chart) III-38

3. JAPAN III-39
A.Market Analysis III-39
Current and Future Analysis III-39
Demographics Drive Market Growth III-39
Table 78: Japanese Population by Age Group (2012) (includes
corresponding Graph/Chart) III-39

Table 79: Japanese 65+ Years Population: 1950-2010
(includes corresponding Graph/Chart) III-40
Strategic Corporate Development III-40
Sekisui Diagnostics - A Key Player III-40
B.Market Analytics III-42
Table 80: Japanese Recent Past, Current and Future Analysis
for Automated and Rapid Microbiological Tests by End-Use
Segment - Clinical Applications (Automated Identification and
Susceptibility Systems, Automated Blood Culture Systems,
Automated Tuberculosis Systems, Streptococcal Infection
Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated and
Rapid Microbiological Tests) and Non-Clinical Applications
Independently Analyzed with Annual Sales Figures in US$
Thousand for Years 2013 through 2020 (includes corresponding
Graph/Chart) III-42

Table 81: Japanese Historic Review for Automated and Rapid
Microbiological Tests by End-Use Segment - Clinical
Applications (Automated Identificationand Susceptibility
Systems, Automated Blood Culture Systems, Automated
Tuberculosis Systems, Streptococcal Infection Rapid Tests,
GC/Chlamydia Rapid Tests, and Other Automated and Rapid
Microbiological Tests) and Non-Clinical Applications
Independently Analyzed with Annual Sales Figures in US$
Thousand for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-43

Table 82: Japanese 15-Year Perspective for Automated and Rapid
Microbiological Tests by End-Use Segment - Percentage
Breakdown of Dollar Sales for Clinical Applications
(Automated Identification and Susceptibility Systems,
Automated Blood Culture Systems, Automated Tuberculosis
Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia
Rapid Tests, and Other Automated and Rapid Microbiological
Tests) and Non-Clinical Applications for Years 2006, 2014 and
2020 (includes corresponding Graph/Chart) III-44

4. EUROPE III-45
A.Market Analysis III-45
Current and Future Analysis III-45
Debt Crisis in Europe Affects Healthcare Industry III-45
European Healthcare System: In a State of Transition? III-45
Ageing Demography - An Opportunity Indicator III-46
Table 83: Population Breakup by Age Group for Select
European Countries: 2011 (as a Percentage of Total
Population) (includes corresponding Graph/Chart) III-47
Clinical Vis-a-vis Non-clinical Applications III-48
What Drives the Requirement Patterns of End-Users? III-48
Proliferation of Automated, and Rapid Tests in Clinical
Applications III-48
Non-clinical Applications III-49
Table 84: European Microbiological Food Safety Tests
(2012): Percentage Share Breakdown of Number of Tests by
Segment - Routine Tests and Pathogen Tests (includes
corresponding Graph/Chart) III-49
B.Market Analytics III-50
Table 85: European Recent Past, Current and Future Analysis
for Automated and Rapid Microbiological Tests by Geographic
Region - France, Germany, Italy, UK, Spain, Russia, and Rest
of Europe Independently Analyzed with Annual Sales Figures
in US$ Thousand for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-50

Table 86: European Historic Review for Automated and Rapid
Microbiological Tests by Geographic Region - France,
Germany, Italy, UK, Spain, Russia, and Rest of Europe
Independently Analyzed with Annual Sales Figures in US$
Thousand for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-51

Table 87: European 15-Year Perspective for Automated and Rapid
Microbiological Tests by Geographic Region - Percentage
Breakdown of Dollar Sales for France, Germany, Italy, UK,
Spain, Russia, and Rest of Europe for Years 2006, 2014 and 2020
(includes corresponding Graph/Chart) III-52

Table 88: European Recent Past, Current and Future Analysis
for Automated and Rapid Microbiological Tests by End-Use
Application - Clinical Applications (Automated
Identification and Susceptibility Systems, Automated Blood
Culture Systems, Automated Tuberculosis Systems,
Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid
Tests, and Other Automated and Rapid Microbiological Tests)
and Non-Clinical Applications Independently Analyzed with
Annual Sales Figures in US$ Thousand for Years 2013 through
2020 (includes corresponding Graph/Chart) III-53

Table 89: European Historic Review for Automated and Rapid
Microbiological Tests by End-Use Application- Clinical
Applications (Automated Identification and Susceptibility
Systems, Automated Blood Culture Systems, Automated
Tuberculosis Systems, Streptococcal Infection Rapid Tests,
GC/Chlamydia Rapid Tests, and Other Automated and Rapid
Microbiological Tests) and Non-Clinical Applications
Independently Analyzed with Annual Sales Figures in US$
Thousand for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-54

Table 90: European 15-Year Perspective for Automated and Rapid
Microbiological Tests by End-Use Application - Percentage
Breakdown of Dollar Sales for Clinical Applications
(Automated Identification and Susceptibility Systems,
Automated Blood Culture Systems, Automated Tuberculosis
Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia
Rapid Tests, and Other Automated and Rapid Microbiological
Tests) and Non-Clinical Applications for Years 2006, 2014 and
2020 (includes corresponding Graph/Chart) III-55

4a. FRANCE III-56
A.Market Analysis III-56
Current and Future Analysis III-56
Product Launch III-56
Strategic Corporate Development III-57
bioMerieux SA - A Key Player III-57
B.Market Analytics III-58
Table 91: French Recent Past, Current and Future Analysis for
Automated and Rapid Microbiological Tests by End-Use
Application - Clinical Applications (Automated
Identification and Susceptibility Systems, Automated Blood
Culture Systems, Automated Tuberculosis Systems,
Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid
Tests, and Other Automated and Rapid Microbiological Tests)
and Non-Clinical Applications Independently Analyzed with
Annual Sales Figures in US$ Thousand for Years 2013 through
2020 (includes corresponding Graph/Chart) III-58

Table 92: French Historic Review for Automated and Rapid
Microbiological Tests by End-Use Application - Clinical
Applications (Automated Identification and Susceptibility
Systems, Automated Blood Culture Systems, Automated
Tuberculosis Systems, Streptococcal Infection Rapid Tests,
GC/ Chlamydia Rapid Tests, and Other Automated and Rapid
Microbiological Tests) and Non-Clinical Applications
Independently Analyzed with Annual Sales Figures in US$
Thousand for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-59

Table 93: French 15-Year Perspective for Automated and Rapid
Microbiological Tests by End-Use Application - Percentage
Breakdown of Dollar Sales for Clinical Applications
(Automated Identification and Susceptibility Systems,
Automated Blood Culture Systems, Automated Tuberculosis
Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia
Rapid Tests, and Other Automated and Rapid Microbiological
Tests) and Non-Clinical Applications for Years 2006, 2014 and
2020 (includes corresponding Graph/Chart) III-60

4b. GERMANY III-61
A.Market Analysis III-61
Current and Future Analysis III-61
Food Safety - A Cause of Concern III-61
Food Safety Regulations in Germany III-61
Strategic Corporate Developments III-62
B.Market Analytics III-63
Table 94: German Recent Past, Current and Future Analysis for
Automated and Rapid Microbiological Tests by End-Use
Application - Clinical Applications (Automated
Identification and Susceptibility Systems, Automated Blood
Culture Systems, Automated Tuberculosis Systems,
Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid
Tests, and Other Automated and Rapid Microbiological Tests)
and Non-Clinical Applications Independently Analyzed with
Annual Sales Figures in US$ Thousand for Years 2013 through
2020 (includes corresponding Graph/Chart) III-63

Table 95: German Historic Review for Automated and Rapid
Microbiological Tests by End-Use Application - Clinical
Applications (Automated Identification and Susceptibility
Systems, Automated Blood Culture Systems, Automated
Tuberculosis Systems, Streptococcal Infection Rapid Tests,
GC/Chlamydia Rapid Tests, and Other Automated and Rapid
Microbiological Tests) and Non-Clinical Applications
Independently Analyzed with Annual Sales Figures in US$
Thousand for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-64

Table 96: German 15-Year Perspective for Automated and Rapid
Microbiological Tests by End-Use Application - Percentage
Breakdown of Dollar Sales for Clinical Applications
(Automated Identification and Susceptibility Systems,
Automated Blood Culture Systems, Automated Tuberculosis
Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia
Rapid Tests, and Other Automated and Rapid Microbiological
Tests) and Non-Clinical Applications for Years 2006, 2014 and
2020 (includes corresponding Graph/Chart) III-65

4c. ITALY III-66
A.Market Analysis III-66
Current and Future Analysis III-66
B.Market Analytics III-67
Table 97: Italian Recent Past, Current and Future Analysis for
Automated and Rapid Microbiological Tests by End-Use
Application - Clinical Applications (Automated
Identification and Susceptibility Systems, Automated Blood
Culture Systems, Automated Tuberculosis Systems,
Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid
Tests, and Other Automated and Rapid Microbiological Tests)

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

New Frontiers in Automated Microbiology: Global Challenges, Emerging Technologies, Competitive Landscape

New Frontiers in Automated Microbiology: Global Challenges, Emerging Technologies, Competitive Landscape

  • $ 21 100
  • Industry report
  • May 2014
  • by Venture Planning Group

“New Frontiers in Automated Microbiology: Global Challenges, Emerging Technologies, Competitive Landscape” is Venture Planning Group's new seven-country strategic analysis of the major business opportunities ...

Emerging Opportunities in the Global Virology and Bacteriology Testing Market

Emerging Opportunities in the Global Virology and Bacteriology Testing Market

  • $ 21 100
  • Industry report
  • June 2014
  • by Venture Planning Group

“Emerging Opportunities in the Global Virology and Bacteriology Testing Market” is a new seven-country strategic analysis of major business opportunities emerging in the infectious disease testing ...

New Frontiers in Coagulation Testing: Global Challenges, Emerging Technologies, Competitive Landscape

New Frontiers in Coagulation Testing: Global Challenges, Emerging Technologies, Competitive Landscape

  • $ 21 100
  • Industry report
  • May 2014
  • by Venture Planning Group

“New Frontiers in Coagulation Testing: Global Challenges, Emerging Technologies, Competitive Landscape” is Venture Planning Group's new seven-country report designed to help current suppliers and potential ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.